Oruka Therapeutics (NASDAQ:ORKA) Director Carl Dambkowski Sells 105,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 105,000 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares in the company, valued at approximately $4,348,624.71. This represents a 58.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oruka Therapeutics Trading Up 3.3%

Shares of ORKA opened at $60.61 on Friday. Oruka Therapeutics, Inc. has a twelve month low of $10.64 and a twelve month high of $91.00. The company has a market cap of $3.66 billion, a P/E ratio of -31.24 and a beta of -0.20. The company’s fifty day simple moving average is $57.73 and its 200-day simple moving average is $40.43.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. Analysts predict that Oruka Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the business. Fairmount Funds Management LLC raised its holdings in shares of Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares in the last quarter. Secure Asset Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $2,475,000. Avoro Capital Advisors LLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at about $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at about $296,000. Finally, Commodore Capital LP raised its holdings in shares of Oruka Therapeutics by 23.5% in the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

ORKA has been the topic of several recent analyst reports. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a research note on Monday, April 27th. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Monday, May 18th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.